| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b08135759c3f4bd00d7ca24d6405133
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7c41e9134a80b7240a43e2d1b065474
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c19ad42cf273dda7ed977ee1aa08b576
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c9b059176ee3dba96438854bb8e789e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-546 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B82Y5-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F5-00 |
| filingDate |
2012-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d0133554401c408630372d3d3723cc8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd418e2a92064ee2960a2fa53ca53a3b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05ceb3d1f8d7140ae2a1af5ee925b409
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_726e332e865c3fed34fe632a8b2285bb |
| publicationDate |
2014-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2014011985-A1 |
| titleOfInvention |
Targeted Cancer Therapy Conjugates Using Porphyrins and Porphyrin-like Molecules and Various Cytotoxic Agents |
| abstract |
Disclosed are targeted in-vivo cancer therapeutics based on the creating conjugate combinations of a porphyrin or porphyrin-like molecule or compound used as a delivery vehicle or vector, coupled with a cytotoxic agent that is released upon binding to a tumor site. The families of porphyrin or porphyrin-like molecules or compounds have a high affinity to bind with cancer cells and are organic structures and are not toxic or rejected by the body. The structure includes a binding site for metals and nano-particles. Benefits of the current invention include: accurate, targeted in-vivo radio and therapeutic agents delivered directly to tumor sites. A benefit of targeted therapy is sparing healthy cells and tissue, thus keeping the host patient healthier which enhances the therapeutic effects of reducing and destroying the cancer tumors. An additional benefit is keeping the patient from discomfort of sickness and the side effects of traditional radio and chemo-therapies. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017218959-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11590233-B2 |
| priorityDate |
2012-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |